TRDA ENTRADA THERAPEUTICS, INC.
Research report · from SEC EDGAR · close 2026-07-13
$6.60 -4.6%
$256.2M mkt cap
executive summary
ENTRADA THERAPEUTICS, INC. (TRDA) is a $256.2M company. Revenue is $25.4M (-87.9% y/y) at a -565% net margin. It is not yet profitable. Our health score is F (21/100). 2 red flags on file. Smart money is buying (1 insider). It may need to raise cash (dilution risk).
Revenue (FY)
$25.4M
-87.9% y/y
⛔Going-concern warning
Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
⛔Bankruptcy-risk zone
Altman Z-Score is in the distress zone (0.73).
who's buying
Insider buys / sells
1 / 6
Cash & ST investments
$76.4M
Operating cash flow
-$128.5M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.